Location
San Francisco Marriott Marquis
780 Mission Street
San Francisco, California
Hotel Phone: (415) 896-1600
Meeting Room
Golden Gate Ballroom — Salon A (B2 Level)
No registration fee is charged for this event. For the in-person symposium in San Francisco, preregistration is required as seating is limited.
Faculty Matthew D Galsky, MD
Lillian and Howard Stratton Professor of Medicine
Icahn School of Medicine at Mount Sinai
Co-Leader, Bladder Cancer Center of Excellence
Associate Director, Translational Research
The Tisch Cancer Institute
New York, New York
Shilpa Gupta, MD
Professor of Medicine
Cleveland Clinic Lerner College of Medicine at Case Western Reserve University
Director, Genitourinary Oncology Program
Taussig Cancer Institute, Cleveland Clinic
Cleveland, Ohio
Andrea Necchi, MD
Associate Professor
Vita-Salute San Raffaele University
Head of Genitourinary Medical Oncology
IRCCS San Raffaele Hospital
Milan, Italy
Moderator Terence Friedlander, MD
Professor of Medicine and Robert and Virginia O’Reilly Family Endowed Chair
Chief, Division of Hematology/Oncology
Zuckerberg San Francisco General Hospital
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California
This activity is supported by educational grants from Genentech, a member of the Roche Group, Johnson & Johnson, and Natera Inc.
Not an official event of the 2026 ASCO® Genitourinary Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.
MODULE 1: Optimal Use of Anti-PD-1/PD-L1 Antibodies for Non-Muscle-Invasive Bladder Cancer (NMIBC)
Rationale for the evaluation of anti-PD-1/PD-L1 antibodies in combination with BCG for patients with BCG-naïve high-risk NMIBC
Design, eligibility criteria and key endpoints of the Phase III CREST and POTOMAC studies evaluating sasanlimab and durvalumab, respectively, in combination with BCG for BCG-naïve high-risk NMIBC
Published efficacy and safety data with sasanlimab combined with BCG in the CREST study
Recent positive outcomes with durvalumab in combination with BCG from the POTOMAC study
Potential role of anti-PD-1/PD-L1 antibodies combined with BCG for BCG-naïve high-risk NMIBC
Long-term findings with pembrolizumab monotherapy for patients with BCG-unresponsive high-risk NMIBC; optimal integration into management algorithms
MODULE 2: Contemporary Management of Muscle-Invasive Bladder Cancer (MIBC)
Long-term data from the Phase III CheckMate 274 trial of adjuvant nivolumab for high-risk MIBC; selection of appropriate candidates for this strategy, including the role of molecular residual disease (MRD) analysis
Design, eligibility criteria and primary and secondary endpoints of the Phase III NIAGARA trial evaluating neoadjuvant durvalumab in combination with gemcitabine/cisplatin followed by radical cystectomy and adjuvant durvalumab monotherapy for patients with MIBC
Published efficacy and safety findings with perioperative durvalumab in the NIAGARA trial
Recent FDA approval of durvalumab with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment after radical cystectomy, for patients with MIBC; current clinical role of this approach
Recent positive outcomes from the Phase III KEYNOTE-905/EV-303 study evaluating perioperative pembrolizumab in combination with enfortumab vedotin for patients with MIBC who are ineligible for or decline cisplatin-based treatment; implications for disease management
Other ongoing Phase III studies evaluating combination approaches with anti-PD-1/PD-L1 antibodies and chemotherapy, chemoradiation therapy, other immune checkpoint inhibitors and/or targeted therapies for patients with MIBC
MODULE 3: Current and Future Role of Novel Intravesical Therapies for Nonmetastatic Urothelial Bladder Cancer (UBC)
Advantages of intravesical delivery systems in administering systemic therapies to patients with nonmetastatic UBC
Available findings from the Phase IIb SunRISe-1 study evaluating the gemcitabine intravesical system and cetrelimab, the gemcitabine intravesical system alone or cetrelimab alone for patients with BCG-unresponsive high-risk NMIBC who are ineligible for or decline radical cystectomy
Recent FDA approval of the gemcitabine intravesical system for the treatment of BCG-unresponsive NMIBC with carcinoma in situ, with or without papillary tumors; selection of appropriate candidates for this strategy
Recent findings from the Phase II SunRISe-4 study evaluating the neoadjuvant gemcitabine intravesical system and cetrelimab versus cetrelimab alone for patients with MIBC who are ineligible for or decline cisplatin and who are scheduled for radical cystectomy
Ongoing studies of the gemcitabine intravesical system with and without cetrelimab for NMIBC and MIBC, such as SunRISe-3, SunRISe-4 and SunRISe-5
Initial safety and efficacy results with the TAR-210 erdafitinib intravesical delivery system for patients with NMIBC and select FGFR alterations; the ongoing Phase III MoonRISe-1 study evaluating TAR-210 versus intravesical chemotherapy for FGFR-altered intermediate-risk NMIBC
MODULE 4: Emerging Utility of Circulating Tumor DNA (ctDNA) Evaluation in the Management of Nonmetastatic UBC
Rationale for the investigation of ctDNA monitoring in nonmetastatic UBC
Prognostic and predictive impact of ctDNA status noted in early-phase and nonrandomized research studies for MIBC, such as ABACUS and TOMBOLA
OS outcomes by ctDNA status in the Phase III IMvigor010 trial comparing adjuvant atezolizumab to observation for MIBC
Rationale for the design of the Phase III IMvigor010 trial
Available outcomes without adjuvant systemic therapy from the ctDNA-negative population of the IMvigor011 trial
Recent topline results indicating statistically significant and clinically meaningful improvements in disease-free survival and overall survival with adjuvant atezolizumab in the ctDNA-positive population of the IMvigor011 trial
Ongoing clinical trials, such as ARCHER, incorporating ctDNA assessment into clinical decision-making for patients with nonmetastatic UBC
Potential clinical utility of ctDNA testing for guiding treatment decision-making and monitoring for recurrence in nonmetastatic UBC
Target Audience
This activity is intended for medical and radiation oncologists, urologists and other healthcare providers involved in the treatment of bladder cancer.
Learning Objectives
Upon completion of this activity, participants should be able to
Appreciate the biological rationale for combining anti-PD-1/PD-L1 antibodies with bacillus Calmette-Guerin (BCG) for patients with non-muscle-invasive bladder cancer (NMIBC), and discuss available data with and the potential role of this novel approach.
Optimize the management of high-risk NMIBC that is unresponsive to BCG, considering the efficacy and tolerability of FDA-endorsed therapies.
Review available clinical trial evidence with novel intravesical therapies for nonmetastatic urothelial bladder cancer, and optimally incorporate these approaches into the care of appropriately selected patients with NMIBC.
Analyze the biological basis for the use of perioperative immune checkpoint inhibitor therapy for patients with muscle-invasive bladder cancer (MIBC), and evaluate available data documenting the efficacy and safety of this strategy.
Develop an understanding of the clinical relevance of circulating tumor DNA (ctDNA) as a prognostic and predictive biomarker in MIBC, and evaluate emerging data documenting the benefit of adjuvant anti-PD-1/PD-L1 antibody therapy for patients with positive ctDNA test results after cystectomy.
Assess the biological rationale for, available research findings with and potential role of promising investigational agents for NMBIC and MIBC.
CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided.
FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
MODERATOR Dr Friedlander — Advisory Committees: Aadi Bioscience, AbbVie Inc, Adaptimmune, Aktis Oncology, Astellas, Bicycle Therapeutics, Bristol Myers Squibb, Gilead Sciences Inc, Merck, Pfizer Inc, Samsung Bioepis; Consulting Agreements: Astellas, EMD Serono Inc, Genentech, a member of the Roche Group; Contracted Research: AbbVie Inc, Bicycle Therapeutics, Flare Therapeutics, Genentech, a member of the Roche Group, Johnson & Johnson, Pfizer Inc.
EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
Supporters
This activity is supported by educational grants from Genentech, a member of the Roche Group, Johnson & Johnson, and Natera Inc.
San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600
Meeting Room
Golden Gate Ballroom — Salon A (B2 Level)
Directions
The San Francisco Marriott Marquis is located just 2 blocks (less than 0.2 miles) from the Moscone Center, where the 2026 ASCO Genitourinary Cancers Symposium is taking place.
This activity is intended for medical and radiation oncologists, urologists and other healthcare providers involved in the treatment of bladder cancer.
No registration fee is charged for this event. For the in-person symposium in San Francisco, preregistration is required as seating is limited.
NOTICE Registration for this event is independent of registration for the 2026 ASCO Genitourinary Cancers Symposium.
IN-PERSON registration for clinicians in practice/healthcare professionals
I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.
Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.
Not an official event of the 2026 ASCO® Genitourinary Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.
